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services with the PCS (p < 0.05). CONCLUSION: The results of
this study indicate that general health status and patient satis-
faction are mutually exclusive variables. Further research is need
to understanding which attributes of patient satisfaction are cor-
related with general health status.
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OBJECTIVES: There is no standard method for providing
national benchmarks of dental care quality based on patient
reports, largely, because it is difﬁcult to create a survey that
covers all topics important to various stakeholders (dentists,
patients and dental care experts) while being short enough for
practical use. The purpose of this project was to use a multi-stage
qualitative research approach to involve stakeholders for the
purpose of developing a tool that would have value to very dif-
ferent audiences. METHODS: Speciﬁc features of dental care
were identiﬁed by a qualitative analysis of three, consecutive data
collections: 1) a search of the dental care quality assessment lit-
erature (which was dominated by clinical studies); 2) audio-tapes
of in-person interviews with dental care experts (primarily payers
and policy makers); and 3) audiovisual-tapes of focus groups
with dental patients. Questions to address each of 117 unique
features were drafted and organized into 20 topic areas. A
shorter version of this question list was created by choosing a
subset of questions that addressed just seven (of 20) topic areas
identiﬁed as the most critical aspects of care by both dental care
experts and dental patients. Finally, in-depth, “think-aloud”
interviews were used to determine the comprehensibility of the
questions and to assess whether they were interpreted as
intended. RESULTS: A 50-item questionnaire was developed
that describes: Dentist Communication, Technical Quality of
Care, Cleanliness of Ofﬁce/Clinic, Treatment Outcome, Access
to Necessary Care, Timely Access to Care, and Quality of Dental
Plan. CONCLUSION: A rigorous program of qualitative
research can be used to develop a content-valid, concise, yet com-
prehensive tool to provide data of potential value to a variety of
stakeholders. Subsequent research will evaluate the statistical
precision of data provided by this questionnaire in a pilot sample
of approximately 2100 dental patients.
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OBJECTIVES: Patient-reported Outcomes (PRO) are used in
clinical studies to assess patients’ treatment beneﬁt. There is an
increased interest in examining PRO claims included in approved
product labels. To date, there is no single database summarizing
PRO claims approved by the FDA or the EMEA by therapeutic
area, type of PROs or sponsors. In order to provide easy access
to this information, Mapi Research Trust and Mapi Values have
developed the PROLabels database. METHODS: Summary
Product Characteristics (SPC) of drugs approved through the
centralized procedure were gathered from the EMEA website
since January 1995. Approved labels of New Molecular Entities
posted on the FDA CDER website since January 1998 were also
examined. Only data pertaining to efﬁcacy endpoints were con-
sidered. Once a PRO claim was identiﬁed in an approved label,
the corresponding product was added to the database. Further
information displayed include: description of clinical studies sup-
porting the claim, the product’s pharmacological action, and
data source. RESULTS: At the date of December 21, 2005, the
database contains 121 records (57 from the FDA and 64 from
the EMEA) for 91 different International Nonproprietary Names
(INN). The ﬁve most represented therapeutic areas include
nervous (32.0%), immune (24.0%), musculoskeletal (18.0%),
genitourinary (14.8%), and respiratory (13.2%) systems. Signs
and symptoms are the most frequently measured PROs while,
HRQOL represents 20.7%. The database can be searched by
INN, commercial name, marketing authorization holder, indica-
tion, PRO, approval date, and agency. CONCLUSIONS: The
PROLabels database is a useful on-line tool to ﬁnd which prod-
ucts have obtained a PRO claim when reviewed by the EMEA
or the FDA. The database will be weekly updated. Other data
sources will be added to include PRO approved through the
mutual recognition/decentralized procedure in Europe and claim
approved in Canada.
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OBJECTIVES: To determine if item-level examination of 12-
month changes in quality of life (QOL) ratings gives qualitatively
different evidence that QOL change occurred as compared to dif-
ference in total scores. METHODS: A total of 258 AD patients
in a clinical trial of nonsteroidal anti-inﬂammatory agents
responded to 13 QOL items at two visits 12 months apart. A
simple difference (later–earlier) was calculated for total scores.
A qualiﬁed change algorithm was applied to the items: ratings
of “good” and “fair” were treated as indistinguishable and dif-
ferences per item were classiﬁed as one of four possible out-
comes: improved, worsened, stayed poor, and stayed “OK” (fair,
good, excellent). A Toulmin diagram permits evaluation of the
strength of evidence supporting a claim that “QOL changed”;
this method was used to compare evidence of QOL change from
the total score and item levels. RESULTS: “Signiﬁcant loss of
QOL” was observed in the treatment (each group mean < -1.0,
p < 0.05), but not the placebo (mean = -0.59, p > 0.3), groups.
Roughly 60% of all change in QOL items was worsening in each
arm; 17–42% of all subjects experienced change in each item.
CONCLUSIONS: Simple difference in total score over 12
months suggested little loss in QOL whereas qualifying change
suggested that at least 17% of any group experienced change on
every item with 60% of all change being worsening. A simple
difference summarizes estimated change, obscuring evidence that
change occurs. The Toulmin diagram suggests that more and
stronger evidence of change was obtained in a qualiﬁed change
approach, which reﬂects change as both improvement and wors-
ening and contemplates alternative explanations for observed
change. Qualiﬁed change provides more and stronger evidence
of change in subjective measures such as QOL.
